Prostate Cancer - Results from #920

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. May 6, 2024

PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI. May 6, 2024

Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis. May 6, 2024

The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study. May 6, 2024

Androgen Deprivation Therapy/Androgen Receptor Signaling Inhibitor Treatments for Prostate Cancer: Pathophysiology and Review of Effects on Cardiovascular Disease. May 6, 2024

Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study. May 6, 2024

Plant-Based Diets and Disease Progression in Men With Prostate Cancer. May 3, 2024

Incidence and Management of Radiation Cystitis After Pelvic Radiotherapy for Prostate Cancer: Analysis from a National Database. May 3, 2024

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis. May 3, 2024

Prostate size ≥ 100 g and its association with long-term outcomes of Retzius-sparing robot-assisted radical prostatectomy. May 3, 2024

Suitability of the MP1000 Platform for Robot-assisted Prostatectomy: A Prospective Randomised Controlled Trial. May 3, 2024

Diagnostic Utility of Artificial Intelligence-assisted Transperineal Biopsy Planning in Prostate Cancer Suspected Men: A Prospective Cohort Study. May 2, 2024

Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). May 2, 2024

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. May 2, 2024

Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance. May 2, 2024

Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. May 2, 2024

Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy. May 1, 2024

Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting. May 1, 2024

A Community-Based Prostate Cancer Screening and Education Program for Asian American Men in Medically Underserved Communities. May 1, 2024

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. May 1, 2024

Page 47 of 1435